SCYX
HEALTHCAREScynexis Inc
AI Insight
What's Moving SCYX Today?
No stock-specific AI insight has been generated for SCYX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.68$10.48
$3.82
Fundamentals
Market Cap$302M
P/E Ratio—
EPS$-3.84
Dividend Yield—
Dividend / Share—
ROE-53.4%
Profit Margin-120.5%
Debt / Equity—
Trading
Volume77K
Avg Volume (10D)—
Shares Outstanding79.4M
SCYX News
22 articles- Net debt of SCYNEXIS, Inc. – FWB:135TradingView·Jun 4, 2026
- Upcoming Stock Splits This Week (June 1 to June 5) – Stay InvestedYahoo Finance·Jun 1, 2026
- SCYNEXIS announces 1-for-8 reverse stock split effective May 29Investing.com UK·May 23, 2026
- SCYNEXIS Announces One-for-Eight Reverse Stock SplitYahoo Finance·May 22, 2026
- SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 11, 2026
- SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·May 7, 2026
- SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney DiseaseYahoo Finance·Mar 31, 2026
- SCYNEXIS Announces $40.0 Million Private PlacementYahoo Finance·Mar 31, 2026
- SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Benzinga·Mar 31, 2026
- SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal TherapyYahoo Finance·Mar 12, 2026
- Scynexis: Q4 Earnings SnapshotYahoo Finance·Mar 4, 2026
- SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 4, 2026
- SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247Yahoo Finance·Feb 26, 2026
- CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsYahoo Finance·Feb 17, 2026
- SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)Yahoo Finance·Jan 28, 2026
- SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247Yahoo Finance·Jan 21, 2026
- SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementYahoo Finance·Dec 22, 2025
- SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSKYahoo Finance·Nov 19, 2025
- Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal InfectionsYahoo Finance·Nov 17, 2025
- Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn SituationYahoo Finance·Nov 10, 2025
- Scynexis: Q3 Earnings SnapshotYahoo Finance·Nov 5, 2025
- SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 5, 2025
All 22 articles loaded
Price Data
Open$3.68
Previous Close$3.82
Day High$3.98
Day Low$3.68
52 Week High$10.48
52 Week Low$3.68
52-Week Range
$3.68$10.48
$3.82
Fundamentals
Market Cap$302M
P/E Ratio—
EPS$-3.84
Dividend Yield—
Dividend / Share—
ROE-53.4%
Profit Margin-120.5%
Debt / Equity—
Trading
Volume77K
Avg Volume (10D)—
Shares Outstanding79.4M
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—